Showing results (61-70 of 69) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 69 results.
Clinical Lung Cancer|December 15, 2023
Detection of Circulating Tumor DNA After Stereotactic Ablative Radiotherapy in Patients With Unbiopsied Lung Tumors (SABR-DETECT)Saurav Verma, Sympascho Young, Thomas A C Kennedy, et al.
Angewandte Chemie (International Ed. in English)|November 8, 2014
Nanoparticle-mediated binning and profiling of heterogeneous circulating tumor cell subpopulationsReza M Mohamadi, Justin D Besant, Adam Mepham, et al.
JAMA Oncology|June 30, 2018
Assessment of the Validity of Nuclear-Localized Androgen Receptor Splice Variant 7 in Circulating Tumor Cells as a Predictive Biomarker for Castration-Resistant Prostate CancerHoward I Scher, Ryon P Graf, Nicole A Schreiber, et al.
The American Journal of Pathology|July 4, 2006
Role of the integrin-binding protein osteopontin in lymphatic metastasis of breast cancerAlison L Allan, Rosamma George, Sharon A Vantyghem, et al.
BMC Cancer|July 8, 2022
Circulating tumor cells detected in follow-up predict survival outcomes in tri-modality management of advanced non-metastatic esophageal cancer: a secondary analysis of the QUINTETT randomized trialEdward Yu, Alison L Allan, Michael Sanatani, et al.
Oncotarget|March 1, 2018
A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209Bernhard Josef Eigl, Kim Chi, Dongsheng Tu, et al.
Head & Neck|November 15, 2011
Detection of circulating tumor cells in advanced head and neck cancer using the CellSearch systemAnthony C Nichols, Lori E Lowes, Christopher C T Szeto, et al.
Clinical Genitourinary Cancer|May 7, 2019
A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205Sebastien J Hotte, Kim N Chi, Anthony M Joshua, et al.
BMC Palliative Care|September 7, 2024
A randomized phase III trial of stereotactic ablative radiotherapy for patients with up to 10 oligometastases and a synchronous primary tumor (SABR-SYNC): study protocolDavid A Palma, Meredith E Giuliani, Rohann J M Correa, et al.
Pageof 7